Skip to main content
SpringerLink
Log in

Tegafur/Uracil

A Viewpoint by Tomoyuki Kato

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22(4): 333–8

    Article  PubMed  CAS  Google Scholar 

  2. Ikeda E, Kodaira S, Teramoto T, et al. Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer-phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration-Study Group of UFTM Therapy for Advanced Colorectal Cancer [in Japanese]. Gan To Kagaku Ryoho 1996; 23: 1291–8

    PubMed  CAS  Google Scholar 

  3. Kusunoki M, Yanagi H, Noda M, et al. The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. Oncol Rep 1999; 6: 547–52

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aichi Cancer Centre Hospital, Chiktisa-ku, Nagoya, Japan

    Tomoyuki Kato

Authors
  1. Tomoyuki Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kato, T. Tegafur/Uracil. Drugs Aging 18, 949 (2001). https://doi.org/10.2165/00002512-200118120-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118120-00006

Keywords

Search

Navigation